Blockchain Registration Transaction Record

Kairos Pharma and Bayer Partner to Target Prostate Cancer Resistance

Kairos Pharma collaborates with Bayer to evaluate ENV-105 with XOFIGO for prostate cancer. Learn about the trial targeting CD105 resistance. Read more at TinyGems.

This collaboration matters because it addresses a critical challenge in prostate cancer treatment: drug resistance. By combining ENV-105, which targets CD105 to overcome resistance, with XOFIGO, an FDA-approved radiopharmaceutical, the partnership could lead to more durable and effective therapies for patients with metastatic castration-resistant prostate cancer. For investors, it highlights Kairos Pharma's innovative approach and potential for significant clinical impact, while for patients, it offers hope for extended survival and improved quality of life.